Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label midostaurin study in aggressive systemic mastocytosis or mast cell leukemia
NL-OMON37318Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in Aggressive Systemic Mastocytosis (ASM) and mast cell leukemia (MCL), sponsored by Novartis. Primary endpoint: overall response rate. Started Jan 2009; status: active, not recruiting.
02
Drugs
midostaurin
03
Conditions
Aggressive Systemic Mastocytosis (ASM)mast cell leukemia (MCL)
Beyond the preview
Go deeper on NL-OMON37318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37318.